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ABSTRACT
Introduction: Despite studies examining
daptomycin non-susceptible (DNS)
Staphylococcus aureus, examination of the
stability and population profiles is limited. The
objective was to evaluate the stability,
population profiles, and daptomycin activity
against DNS isolates.
Methods: The stability of 12 consecutive
clinical DNS strains was evaluated by
minimum inhibitory concentration (MICs)
and population analysis profiles before and
after 5 days of serial passage. Two pairs of DNS
S. aureus having the same daptomycin MIC but
different daptomycin population profiles were
evaluated via an in vitro pharmacokinetic/
pharmacodynamic (PK/PD) model of simulated
endocardial vegetations for 96 h against
daptomycin 6 and 10 mg/kg/day. The
sequence of mprF was determined for these
isolates before and after 96 h of daptomycin
exposure in the in vitro PK/PD model.
Results: Daptomycin MIC values were 2–4 mg/L
(via Microscan) for the 12 clinical isolates; 9 were
confirmed DNS and 3 were within 1 tube dilution
of Microscan (daptomycin MIC 1 mg/L). All were
stable to serial passage. There was variation in
the isolates susceptibility to daptomycin on
population analysis (daptomycin population
AUC 14.01–26.85). The killing patterns of
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daptomycin 6 and 10 mg/kg/day differed
between isolates with a left-shift and right-
shift population profile to daptomycin. Two
strains developed additional mprF mutations
during daptomycin exposure in the in vitro PK/
PD model resulting in P314L, L826F, S337L and
a novel Q326Stop mutation.
Conclusions: The collection of DNS isolates was
stable and displayed variation in susceptibility
to daptomycin on population profile. Further
research examining this clinical relevance is
warranted.
Keywords: Daptomycin; Daptomycin non-
susceptible; Infectious diseases; mprF;
Staphylococcus aureus
INTRODUCTION
Daptomycin is a cyclic lipopeptide antibiotic
with activity against Gram-positive organisms
that received approval from the United States
Food and Drug Administration in September,
2003 [1]. It is a concentration-dependent
bactericidal antibiotic that acts by binding to
and inserting into the bacterial cytoplasmic
membrane resulting in rapid depolarization
and deregulation of several cell functions such
as DNA, RNA and protein synthesis [2–4].
Daptomycin susceptibility in Staphylococcus
aureus is defined as a minimum inhibitory
concentration (MIC) of B1 mg/L and any
strain with an MIC [1 mg/L is considered
daptomycin non-susceptible (DNS) [5].
The development of DNS in S. aureus
laboratory studies, clinical trials, and post-
marketing surveillance has been relatively low.
Spontaneous mutagenesis in S. aureus for DNS
appears at a rate of less than 1010 [6].
Staphylococcus aureus with DNS can be
obtained via extended serial passage with
increasing daptomycin concentrations and via
chemical mutagenesis. An in vitro model
evaluated standard vancomycin and
daptomycin dosing regimens against 5 clinical
strains of S. aureus that developed DNS in vivo
[7]. The DNS could only be replicated in vitro in
1/5 of these strains and with vancomycin but
not daptomycin exposure. Interestingly, the
DNS in this S. aureus strain was unstable and
reverted back to susceptible upon passage on
antibiotic free media. Only 7 of 120 patients in
the phase III trial for S. aureus bacteremia and
infective endocarditis trial developed isolates
with DNS [8]. Evaluation of 22,858 S. aureus
isolated in North America from 2005 to 2010
revealed only 14 strains with a daptomycin MIC
of C2 mg/L, and no trend indicating increasing
MICs was noted [9].
Daptomycin non-susceptibility in S. aureus
does not appear to be an all or nothing
phenomenon, but instead a series of
incremental changes that increase the MIC
[10–15]. To date, four main genetic changes
(mprF, yycG, rpoB/rpoC, dltABCD) have been
associated with increased MIC and DNS in S.
aureus. Mutations in or overexpression of the
mprF gene is commonly found in both
laboratory derived and clinical DNS isolates
[11–14]. Increased quantities of the MprF
protein, a lysylphosphatidylglycerol synthase,
is thought to contribute to DNS by affecting the
composition of the cell membrane via
translocation of positively charged
phospholipids to the outer side of the
cytoplasmic membrane and by lysinylation
of membrane phosphatidylglycerol (PG) to
generate lysyl-PG (LPG) thereby increasing
positive surface charge [14–16]. Recently
mutations in the phospholipid biosynthesis
genes cardiolipin synthase (cls2) and
CDP-diacylglycerol-glycerol-3-phosphate 3
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phosphatidyltransferase (pgsA) have been found
in clinical DNS strains [17]. Another altered
protein sometimes found in DNS strains is
YycG, which is one of two components of a
response regulator system involved in the
metabolism of the cytoplasmic membrane and
cell wall [11]. The proteins RpoB and RpoC,
which comprise the b and b0 subunit of RNA
polymerase, have also been found with amino
acid substitutions in DNS S. aureus strains [11].
Recently, a single nucleotide polymorphism in
rpoB from a laboratory derived DNS S. aureus was
associated with decreased negative surface
charge, increased cell wall thickness, and both
vancomycin and daptomycin heteroresistance
[18]. Additionally, increased expression of the
dltABCD operon increases D-alanylation of cell
wall teichoic acids contributing to an increase
in positive surface charge [13]. Recent work has
also suggested membrane proteins may
augment the bactericidal effects of
daptomycin, and alteration or loss of these
proteins may contribute to DNS [15]. It has also
been proposed that changes in carotenoid
biosynthesis in S. aureus can increase
membrane rigidity and contribute to increases
in daptomycin MIC values [19]. Overall, DNS S.
aureus strains show altered membrane potential,
changes in membrane fluidity, increased
positive membrane surface charge, and
decreased membrane depolarization [10–15]. It
is hypothesized that the increase in cytoplasmic
membrane surface charge repels the active
daptomycin-Ca2? complex and therefore
impedes interaction of daptomycin with the
membrane [10, 20]. There are likely other
genetic changes that contribute to DNS in S.
aureus as strains exhibiting elevated MICs often
have only some of the changes mentioned
above [21–24]. There is still much room for
discovery of novel cell membrane and genetic
changes in DNS strains of S. aureus.
We have observed that some of the S. aureus
strains identified as DNS by the clinical
microbiology laboratory at our institution
using Microscan (Dade Behring, Deerfield, IL,
USA) were actually susceptible via broth
microdilution following passage on antibiotic
free agar or time being stored at -80 C. This
observation led us to question the stability of
these isolates. Additionally, previous in vitro
work we have done with DNS strains has
demonstrated variable activity of daptomycin
[25, 26]. In some cases, daptomycin regimens of
10 mg/kg per day maintain antibacterial activity
and led us to hypothesize that some S. aureus
strains with DNS may still be treatable with
daptomycin. The objectives of this study were
to evaluate the stability of DNS strains from the
clinical microbiology laboratory and to evaluate
the activity of daptomycin regimens against




Twelve consecutive clinical S. aureus strains,
each having a daptomycin MIC of C2 mg/L,
were collected from the clinical microbiology
laboratory beginning in May 2009 and were
evaluated for stability of DNS. All isolates were
transported from the clinical microbiology
laboratory to our laboratory on the original
blood agar isolation plate within hours of
obtaining the clinical microbiology laboratory
susceptibility results to prevent any passes.
Antimicrobials
Daptomycin analytical grade powder was
obtained from Cubist Pharmaceuticals,
Lexington, MA, USA.
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Media
Mueller–Hinton broth II (MHBII, Difco, Detroit,
MI, USA) supplemented to 50 mg/L calcium was
used for daptomycin susceptibility testing
according to Clinical and Laboratory Standards
Institute (CLSI) guidelines and MHBII
supplemented to 75 mg/L was used for in vitro
model experiments to account for calcium
binding to albumin. Colony counts were
determined using Tryptic Soy Agar (TSA; Difco,
Detroit, MI, USA) plates. Mueller–Hinton agar
prepared from MHBII supplemented with
50 mg/L of calcium and 15 g/L of BactoTM Agar
(Beckton, Dickson & Company, Sparks, MD,
USA) was used for population analysis profiles
(PAP).
Serial Passage
All isolates confirmed as DNS by our laboratory
were passed on TSA five consecutive times.
Isolates with a daptomycin MIC remaining
C2 mg/L (±1 tube dilution standard error)
after 5 serial passages were defined as stable
DNS S. aureus strains and isolates reverting back
to a daptomycin MIC of \1 mg/L were defined
as unstable DNS S. aureus strains.
Susceptibility Testing
The MICs of daptomycin obtained by Microscan
and for the isolates obtained with each serial
passage were confirmed by broth microdilution
(BMD) using an inoculum of 106 CFU/milliliter
(mL) in duplicate according to CLSI standard
methods and by Etest according to the
manufacturer’s guidelines [5]. S. aureus ATCC
25923 was used as a control strain. After greater
than 2 years of storage at -80 C the daptomycin
MIC of all isolates was retested to assess the effect
of storage on the stability of the MIC.
Molecular Biology
All strains were characterized for SCCmec type,
Panton-Valentine Leukocidin (PVL) status, and
agr function and group by previously described
methods [27–31]. S. aureus isolates were
evaluated by pulse field gel electrophoresis
(PFGE) using SmaI-digested DNA, as described
previously [32]. Gels were run at 6 V/cm, 14 C,
at an included angle of 120, on a 1.2% agarose
gel with pulse times of 5–35 s for 21 h. Strain
relatedness was determined by visual inspection
of the gel using the criteria of Tenover et al. and
DICE coefficient using BioNumerics Software




Fifty microliters of a *108 CFU/mL suspension
of each strain was plated onto MHA plates
with calcium containing daptomycin
(concentrations ranging from 0.5 to 6 mg/L)
using an automatic spiral plating device (WASP;
DW Scientific, West Yorkshire, UK). After 48 h
of incubation at 37 C, colony counts were
determined using an automated colony
counter (Synoptics Limited, Frederick, MD,
USA). The lower limit of detection for colony
count was 2 log10 CFU/mL. Curves were
constructed by plotting colony counts (log10
CFU/mL) versus concentration. Strain SA-684,
previously determined to be stable to passage,
was used as a control strain [15].
In Vitro Model Experiment
Two pairs of DNS S. aureus strains with the same
MIC values by Microscan and BMD but
displaying different PAPs (left shift vs. right
shift) were evaluated in an in vitro
190 Infect Dis Ther (2013) 2:187–200
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pharmacokinetic/pharmacodynamic (PK/PD)
model of simulated endocardial vegetations.
Simulated Endocardial Vegetations
Organism stocks were prepared by creating
lawns on TSA plates and incubating at 37 C
overnight. Organisms were swabbed from the
growth plates into five mL test tubes of MHBII,
diluted 1:10 and resulting in a concentration of
approximately 1010 CFU/mL. Simulated
Endocardial Vegetations (SEVs) were prepared
in 1.5 mL siliconized eppendorf tubes by mixing
0.05 mL of organism suspension (final
inoculum 109 CFU/0.5 g), 0.5 mL of human
cryoprecipitate from volunteer donors
(American Red Cross, Detroit, MI, USA),
0.025 mL of platelets. Bovine thrombin (5,000
units/mL) 0.05 mL, was added to each tube after
insertion of a sterile monofilament line into the
mixture. The resultant SEVs were then removed
from the eppendorf tubes with a sterile
21-gauge needle and introduced into the
model. This methodology results in SEVs
consisting of approximately 3–3.5 g/dL of
albumin and 6.8–7.4 g/dL of total protein.
In Vitro PK/PD Model
An in vitro model, consisting of a 250 mL two
compartment glass apparatus with ports where
the SEVs were suspended, was utilized for all
simulations. The apparatus was prefilled with
media and antibiotics were administered as
boluses over a 96 h time period into the
central compartment via an injection port.
Antibiotic regimens evaluated included
daptomycin 6 mg/kg every 24 h (peak,
98.6 mg/L; average half-life, 8 h) and
daptomycin 10 mg/kg every 24 h (peak
141.1 mg/L; average half-life 8 h) [34]. The
model apparatus was placed in a 37 C water
bath throughout the procedure and a magnetic
stir bar was placed in the media for thorough
mixing of the drug in the model. Fresh media
was continuously supplied and removed from
the compartment along with the drug via a
peristaltic pump (Masterflex, Cole-Parmer
Instrument Company, Chicago, IL, USA) set to
simulate the half-lives of the antibiotics. All
models were performed in duplicate to ensure
reproducibility.
Pharmacodynamic Analysis
Two SEVs were removed from each model (total
of 4) at 0, 4, 8, 24, 32, 48, 56, 72 and 96 h. The
SEVs were homogenized and diluted in cold
saline and then plated onto TSA plates. Plates
were incubated at 37 C for 24 h at which time
colony count was performed. The total
reduction in log10 CFU/g over 96 h was
determined by plotting time kill curves.
Bactericidal activity (99.9% kill) was defined as
a C3 log10 CFU/g reduction in colony count
from the initial inoculum, bacteriostatic activity
was defined as a \3 log10 CFU/g reduction in
colony count from the initial inoculum, and
inactive was defined as no observed reductions
in initial inocula. The time to achieve a 99.9%
reduction was determined by linear regression
or visual inspection (if r2 C 0.95). Susceptibility
was performed on the 96 h sample by broth
microdilution.
Pharmacokinetic Analysis
Pharmacokinetic samples were obtained in
duplicate through the injection port of each
model at 0.5, 1, 2, 4, 8, 24, 32, 48, 56, 72 and
96 h for verification of target antibiotic
concentrations. All samples were stored at
-70 C until ready for analysis. Concentrations
of daptomycin were determined by
Infect Dis Ther (2013) 2:187–200 191
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microbioassay utilizing Micrococcus luteus ATCC
9341. Briefly, blank 00 disks were placed on a
pre-swabbed plate of appropriate antibiotic
medium and spotted with 10 lL of the
standards or samples. Each standard was tested
in duplicate. Plates were incubated for 18–24 h
at 37 C at which time the zone sizes were
measured. The half-lives, area under the curve
(AUC), AUC/MIC and peak concentrations of
the antibiotics were determined by the
trapezoidal method utilizing PK Analyst
software (Version 1.10, MicroMath Scientific
Software, Salt Lake City, UT, USA).
Resistance
Development of resistance in the SEV model was
evaluated at multiple time points throughout the
simulation at 24, 48, 72, and 96 h. 100 lL samples
from each time point were plated on MHA plates
containing three times the drug’s MIC to assess
the development of resistance. Plates were then
examined for growth after 24–48 h of incubation
at 37 C. MICs were determined for all mutants
identified via this method (by microdilution and
Etest as described above).
Statistical Analysis
Changes in CFU/g at 24, 48, 72, and 96 h were
compared by two-way analysis of variance with
Tukey’s post hoc test. A P value of B0.05 was
considered significant. Paired continuous data
was evaluated with a paired t test. All statistical
analyses were performed using SPSS Statistical
Software (Release 19.0, SPSS, Inc., Chicago, IL,
USA).
mprF Sequencing
All 4 isolates placed in the SEV in vitro model
and the isolates recovered at 96 h were
evaluated for mutations in the mprF gene.
The mprF genes were amplified by PCR using
previously described primers [12]. The
products were sequenced in both directions
by an automated dideoxy chain termination
method by the Applied Genomics Technology
Center, Wayne State University. Nucleotide
sequence analysis was performed with
DS Gene 1.5 (Accelrys, Inc. San Diego, CA,
USA).
Membrane Potential Measurements
Membrane potential was compared between
the stable DNS S. aureus strains and the
daptomycin susceptible parent (when
available and confirmed isogenic by PFGE).
Strains were grown to early exponential phase
in 20 mL of SMHB, pelleted, washed twice with
HEPES buffer (pH 7.2, containing 50 mg/L
Ca2?) and then re-suspended in HEPES
(OD600 = 0.2). Aliquots were transferred to a
cuvette containing a stir bar, then KCl
(100 mM) was added and the cuvette was
placed in the heated chamber of a
FluoroMax-3 spectrofluorometer (kex = 622 nm
and kem 670 nm at 37 C) (Horiba Jobin–Yvon
Inc., Edison, NJ, USA). Cells were incubated
with the membrane potential-sensitive dye
DiSC3 (0.1 mg/mL) for 10 min. Conditions
included no antibiotic, nisin (25 mg/L)
and daptomycin (8 mg/L). The membrane-
depolarizing activity of daptomycin over
60 min was calculated as follows: %
depolarization = [(Fd - Fc)/(Fn - Fc)] 9 100, where
Fd, Fc and Fn are fluorescence measurements with
daptomycin, no antibiotic and nisin, respectively.
Results are expressed as the mean of two
independent experiments.
This article does not contain any studies
with human or animal subjects performed by
any of the authors.
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RESULTS
MICs as determined by both Microscan and
BMD for the twelve DNS S. aureus isolates are
displayed in Table 1. As can be seen, all isolates
had the Microscan MICs confirmed by BMD
(within 1 tube dilution standard error). The
spread for MIC values was as follows: three
isolates with 2 mg/L (Microscan) and 1 mg/L
(BMD), three isolates with 2 mg/L (Microscan/
BMD), three isolates with 4 mg/L (Microscan)
and 2 mg/L (BMD), and three isolates with
4 mg/L (Microscan/BMD). All isolates were
stable over five serial passages on drug free
TSA. Etest MICs confirmed the daptomycin MIC
value within 1 tube dilution. Examination of
the twelve isolates by daptomycin population
analysis revealed both left-shift and right-shift
profiles within the 4 MIC value groups (Fig. 1a–
d). Additionally, the daptomycin AUC values
(Table 1) increase as the MIC values increase
(Table 1). Retesting of the isolate’s daptomycin
MIC values by BMD after greater than 2 years of
storage at -80 C revealed that the MIC values
were stable (±1 tube dilution standard error) for
11/12 isolates (Table 1). One isolate, R6827,
displayed a daptomycin MIC decrease from 4
to 0.5 mg/L on retesting after storage.
Molecular characterization of the twelve
strains is displayed in Table 1. The activity of
daptomycin against 2 selected pairs (4 isolates
total) in the in vitro PK/PD model of SEVs with
the same MIC values but differing daptomycin
PAPs is shown in Fig. 2a–d. A daptomycin dose
response relationship was observed for all four
strains. The daptomycin 6 mg/kg regimen
Table 1 Minimum inhibitory concentration values, daptomycin population analysis area under curve (AUC) values and
molecular characteristics
Isolate MIC value (mg/L) DAP AUC SCCmec USA PVL AGR
Initial Storage
Microscan BMD BMD Type Function
R6297 2 1 1 14.01 2 - - 2 -
R6515 2 1 1 16.87 2 - - 2 -
R6738 2 1 1 18.08 4 300 ? 1 -
R6212 2 2 2 18.45 2 - - 2 ?
R6737 2 2 2 20.03 2 - - 2 -
R6516a 2 2 2 22.09 4 - - 1 -
R6003 4 2 4 22.14 2 - - 2 -
R6253 4 2 2 23.66 4 300 ? 1 ?
R6747 4 2 2 22.28 2 - - 2 -
R6219 4 4 2 20.68 4 300 - 1 ?
R6255 4 4 4 26.85 2 - ? 2 -
R6827 4 4 0.5 21.24 4 300 ? 1 ?
BMD broth microdilution, DAP daptomycin, SCCmec Staphylococcal cassette chromosome mec, USA Staphylococcal USA
clone type, PVL Panton-valentine leukocidin (?present, -absent), AGR accessory gene regulator (function: ?functional,
-dysfunctional)
a USA clone type could not be interpreted from PCR
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initially had sustained bactericidal activity in
the first 24 h against isolates with a left-shift
population profile (R6003 and R6219) (Fig. 2a).
In contrast, isolates with the same MIC value
and a right-shift profile (R6253 and R6255)
displayed bactericidal activity at 8 h but
regrowth at 24 h. The two left-shift isolates
(R6003 and R6219) began to gradually regrow
after 24 h eventually losing their bactericidal
activity. In contrast, the two right-shift isolates
displayed substantial killing and a more rapid
regrowth with the 24 h dose before leveling
off. The regimen of daptomycin 6 mg/kg
maintained bactericidal activity against R6255
at 96 h. No mutants were recovered.
Observed pharmacokinetic parameters were
94.23–109 mg/L and 6.78–7.42 h.
The isolates recovered at 96 h from the
simulations of daptomycin 6 mg/kg did not
have any change in MIC value from the initial
isolates. However, examination of the
population profiles revealed a rightward shift
and increase in AUC. The AUC increased from 0
to 96 h for both R6003 (22.4 vs. 27.3) and R6219
(20.68 vs. 26.15). For isolates with an initial
profile with a right shift, the AUC increase from
0 to 96 h for R6253 (23.66 vs. 27.31) and for
R6253 (26.85 vs. 27.43) was less pronounced.
Fig. 1 Population analysis proﬁles for a Isolates with
MIC values of 2 mg/L (Microscan) and 1 mg/L (Broth
Microdilution, BMD). b Isolates with MIC values of
2 mg/L (Microscan/BMD). c Isolates with MIC values of
4 mg/L (Microscan) and 2 mg/L (BMD). d Isolates with
MIC values of 4 mg/L (Microscan/BMD)
194 Infect Dis Ther (2013) 2:187–200
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All initial isolates evaluated in the in vitro
PK/PD SEV model (R6003, R6219, R6253, and
R6255), and derivatives recovered after 96 h of
exposure to a simulated regimen of daptomycin
6 mg/kg/day, underwent sequence analyses of
mprF. Both R6003 (P314L and E692Q) and
R6253 (P314L) initially possessed mutations
with no additional changes developing during
further daptomycin exposure. Strain R6219 had
a L826F mutation initially and acquired a
Q326Stop mutation during exposure to the
simulated regimen of 6 mg/kg/day. Lastly,
R6255 initially possessed an E692Q mutation
and acquired the S337L mutation during
daptomycin exposure.
The activity of daptomycin 10 mg/kg against
the four tested isolates revealed a similar pattern
as the daptomycin 6 mg/kg regimen.
Daptomycin 10 mg/kg was bactericidal at 4
and 8 h against the two left-shift profile
isolates (R6003 and R6219) with slow regrowth
occurring for both strains by 96 h (Fig. 2b). In
Fig. 2 a Activity of daptomycin 6 mg/kg against
daptomycin left-shift strains R6003 & R6219. b Activity
of daptomycin 10 mg/kg against daptomycin left-shift
strains R6003 and R6219. c Activity of daptomycin
6 mg/kg against daptomycin right-shift strains R6253 &
R6255. d Activity of daptomycin 10 mg/kg against
daptomycin right-shift strains R6253 and R6255. DAP 6
Daptomycin 6 mg/kg/day, DAP 10 daptomycin 10 mg/kg/
day, GC growth control
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contrast, against the right-shift isolates (R6253
and R6255) daptomycin 10 mg/kg resulted in
multiple cycles of colony count decrease
followed by regrowth. Bactericidal activity was
maintained at 96 h for the two right-shift
isolates. No mutants were recovered and
isolates displayed no difference in MIC values
at 96 h. Observed pharmacokinetic parameters
ranged 139.8–144.3 mg/L and 6.9–8.3 h.
One daptomycin susceptible isogenic pair
from the same patient (R6194, daptomycin MIC
value 0.25 mg/L, and R6212 daptomycin MIC
value 2 mg/L, clonality confirmed by PFGE) was
available for depolarization testing. As can be
seen in Fig. 3, the ability of daptomycin
to depolarize the cytoplasmic membrane
decreased from 35.57 ± 2.12% for R6194 to
2.62 ± 5.29% for R6212, P = 0.045.
DISCUSSION
While the occurrence of DNS in S. aureus is
relatively rare, there is still much room for
discovery on mechanisms of resistance and
optimal treatment. While multiple studies
have examined both genetic and phenotypic
changes found in both laboratory derived and
clinical DNS S. aureus, limited work has
examined the population profiles or stability
of these strains. Additionally, to our knowledge
no previous work has attempted to evaluate the
relationship between daptomycin activity and
the daptomycin PAPs of DNS S. aureus strains.
In the current study, we found all 12 of the
clinical DNS S. aureus strains to be stable in
nature as they did not revert to susceptible after
serial passage on drug free agar. Previous work
examining laboratory derived and clinical DNS
S. aureus strains has revealed the occurrence of
an unstable DNS S. aureus phenotype. A DNS S.
aureus strain recovered previously from an
in vitro PK/PD model reverted back to its
susceptible state after serial passage on drug
free agar [35]. Additionally, examination of the
resistant subpopulations from a clinical isogenic
daptomycin susceptible/DNS pair, SA-675
and SA-684, revealed that the resistant
subpopulations were unstable [15].
Additionally, we found the majority (11/12) of
strains to be stable in daptomycin MIC values
after over 2 years of storage at -80 C. A recent
paper examining daptomycin susceptible S.
aureus strains found an overall decrease in MIC
values after storage when tested by Etest [36].
This is in contrast to our study in which all but
one strain was stable on repeat testing over two
years later. These differences may be due to the
Fig. 3 Cytoplasmic membrane depolarization of the
isogenic pair. a R6194 with daptomycin minimum
inhibitory concentration of 0.25 mg/L and b R6212 with
daptomycin minimum inhibitory concentration value of
2 mg/L. Black lines show results with nisin, dark grey lines
show results with daptomycin, and light grey lines show
results for control
196 Infect Dis Ther (2013) 2:187–200
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testing method (Etest vs. BMD) or the MIC
stability of daptomycin susceptible versus
daptomycin non-susceptible S. aureus. While it
appears from our work that the majority of all
daptomycin non-susceptible clinical strains are
indeed stable, further research in this area is
needed to confirm these findings, as most
studies to date have not examined the stability
of DNS S. aureus clinical isolates.
In this study, we found variation in the
susceptibility to daptomycin when the isolates
were examined by population analysis with
some isolates displaying prominent left or
right shifts. Previous work has found the
occurrence of daptomycin heteroresistance in
both daptomycin susceptible and DNS S. aureus
strains. Examination of the previously
mentioned clinical isogenic pair, SA-675 and
SA-684, by daptomycin population analysis
revealed a heterogeneous profile [15].
Examination of a series of S. aureus isolates,
ranging from daptomycin susceptible to DNS,
recovered from a patient receiving high-dose
daptomycin therapy by daptomycin population
analysis revealed the presence of daptomycin
heteroresistance on visual inspection both
before and after the development of DNS [37].
In our study we also found a shift in the profile
from the isolates recovered from the in vitro
model after 96 h of exposure to daptomycin.
This is consistent with the shift seen in clinical
pairs analyzed after in vivo exposure to
daptomycin [15, 37].
Examination of the impact of a DNS S. aureus
daptomycin population profile on the activity
of daptomycin in the in vitro PK/PD model of
SEVs revealed unique killing patterns. The two
isolates with left-shift profiles displayed one
initial decrease in colony counts followed by a
gradual regrowth, while the two right-shift
profile isolates displayed multiple cycles of
killing and regrowth. The extent of the
antimicrobial activity may also be explained
by the daptomycin PAPs. Compared to R6003,
R6219 exhibited a greater decrease in colony
counts when exposed to both daptomycin 6
and 10 mg/kg in the in vitro PK/PD SEV model
despite having the same/higher daptomycin
MIC value. These increases in susceptibility to
daptomycin may be explained by the smaller
AUC of the daptomycin PAP of R6219 (AUC
20.68) compared to R6003 (AUC 22.14). No
correlation was observed, however, between the
daptomycin PAP/AUC and the colony counts at
72–96 h in the in vitro PK/PD model.
Examination of our strains for mutations in
the mprF gene revealed common mutations
previously described including the E692Q,
P314L, L826F and S337L. The finding of a
premature stop codon, Q326Stop, in the
R6219 96 h isolate after daptomycin 6 mg/kg
exposure is interesting as its position would be
expected to interrupt the functional C-terminal
domain of the mprF protein. Previous work has
shown the mprF protein is comprised of two
functional domains, the C-terminal and
N-terminal. While the C-terminal could
independently complete lysinylation of
membrane phospholipids, the N-terminal was
incapable of completing functions without the
assistance of the C-terminal domain. The
Q326Stop mutation would logically render the
mprF protein non-functional.
While our study is novel in examining a
large collection of DNS S. aureus strains for
stability and PAP, it does have limitations.
Firstly, due to the relative rarity of DNS S.
aureus, our collection of examined isolates is
small at 12 and we were only able to obtain a
single daptomycin susceptible—DNS isogenic
pair for comparison evaluation. We also used
standard inocula (log 106 CFU/mL) for broth
microdilution and Etest susceptibility testing
per CLSI and manufacturer’s instructions,
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respectively. The results may have been
different if we employed a high inoculum for
susceptibility testing (109 CFU/mL) as was done
for the PAP and in vitro PK/PD model of SEVs.
Our study is also limited as it focused on the
most common gene mutation in DNS S. aureus,
mprf, and did not examine the isolates for
mutations or changes in expression of other
genes known to be involved in DNS S. aureus.
Lastly, our isolates are from a single geographic
area (Detroit, MI, USA) with an established
history of cutting edge resistance in S. aureus
and may not be representative of resistance
patterns in other areas of the country.
CONCLUSION
All 12 DNS S. aureus isolates were stable and
displayed different degrees of susceptibility when
examined by PAP. To our knowledge, this is the
first study to examine such a large collection of
clinical DNS S. aureus strains and confirm their
stability. This is also the first study to examine
the impact of the daptomycin PAP on the
activity of both standard and high dose
simulated daptomycin. Additionally, an
organism with a unique mutation in mprF,
Q326Stop, which would likely render the mprF
protein non-functional, was discovered. The
findings are clinically relevant because for some
organisms the daptomycin AUC predicted
antimicrobial activity or killing pattern better
than the MIC value by BMD. This highlights the
need to consider the whole population of
bacteria when discussing susceptibility or the
development of resistance. Despite previous
reports that some aspects of DNS may be
inducible and unstable, eleven of our twelve
isolates displayed stable resistance even after
2 years of freezer storage confirming that DNS
can frequently be a stable and not transient
phenomenon in S. aureus. Daptomycin should
continue to be utilized appropriately to
minimize resistance and preserve its efficacy.
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